Therapeutic concentrations of amphotericin B in serum were measured by reversed-phase liquid chromatography with detection at 386 nm. Complete recovery of the drug and the internal standard from a l-ml serum sample was achieved by pretreating the sample with guanidine hydrochloride and extracting it with a disposable reversed-phase phenyl extraction column. The method was sensitive to 0.005 ,ug of amphotericin B per ml and linear to at least 5 ,ug/ml. Coehicients of variation were 4.8% within-run and 6.3% between-run.
assaying the drug in biological fluids hampered attempts at therapeutic monitoring of the drug.. In 1977, Nilssoh-Ehle and colleagues (8) described a liquid chromatographic assay suitable for clinical use. This method provided the speed, simplicity, and precision which microbiological assays lack. Two subsequent chromatographic assays (6, 7) incorporated internal standards (ISTD) to correct for unpredictable variations inherent in a nonstandardized procedure. None of the above methods involved actual extraction of the drug before chromatography, however, but involved instead precipitation of protein in the specimen by the addition of methanol or acetonitrile. After centrifugation, supernatants were injected into the chromatograph. There are at least two deficiencies in the protein precipitation technique (5) . First, precipitation of protein is slow and incomplete. The supernatant contains some protein, as well as other nonprecipitating material, which can clog chromatographic equipment and interfere with the analysis. Second, some of the drug may remain bound to protein and precipitate with it, especially if the drug is relatively hydrophobic, as is amphotericin B. Indeed, Mayhew et al. (7) reported recovering only 53 to 61% of the amphotericin B added to human plasma and suggested that the rest of the drug remained bound to protein.
In this paper I describe a liquid chromatographic assay for amphotericin B This was then mixed with 45 ml of 1% aqueous sodium dodecyl sulfate (SDS). This stock solution (100 ,ug/ml) was stored at -70°C. To make the working standard solution (1 jxg/ml), I combined 1 ml of stock solution, 1.5 ml of 1% SDS, and 97.5 ml of water (total volume, 100 ml). This solution was stored at 1-ml aliquots at -70°C.
Extraction of samples. Samples (serum, aqueous standard, cerebrospinal fluid [CSF], etc.) (1 ml) were combined with 200 ,ul of ISTD solution and 2 ml of 6 M guanidine hydrochloride. After brief mixing, each sample was passed immediately through a separate, disposable phenyl extraction column ("Bond-Elut" PH, catalog no. 608101; Analytichem International, Harbor City, Calif.). Before analysis, the column was washed with one filling of methanol and then one filling of water. The sample was applied and allowed to run through, and the column was rinsed with another filling of water and allowed to drain. The drug and the ISTD were then eluted immediately from the column into a small test tube with 500 ,ul of acetonitrile-EDTA (prepared by combining 75 ml of acetonitrile with 25 ml of 5 mM disodium EDTA). SDS (1%) solution (200 ,ul) was mixed with the extract. Because of the instability of amphotericin B in the specimen after mixing with guanidine, the above steps were completed for one sample before the next sample was extracted. Amphotericin B was very stable in the final extract after SDS was added. For calibration, a 1-ml aliquot of the amphotericin B working standard solution was thawed and immediately extracted as described above.
Chromatography (3) . In this assay, 1 ml of specimen is diluted serially into 1-ml portions of antibiotic medium 3 (Difco Laboratories, Detroit, Mich.). Each tube is then inoculated with Candida albicans and incubated at 35°C overnight. The dilution factor of the highest dilution in which no growth is visible is multiplied by the MIC for the culture (typically 0.04 ,ug/ml) to obtain the concentration of drug in the specimen.
Interference. Unused portions of 64 sera received for general clinical laboratory testing were carried through the amphotericin B determination. Sera examined were from patients known to be receiving cardioactive drugs (digoxin, procainamide, lidocaine, and quinidine), anticonvulsant drugs (phenobarbital, phenytoin, primidone, and carbamazepine), aminoglycosides (amikacin, gentamicin, and tobramycin), and antifungal agents (5-fluorocytosine and ketoconazole). Chromatograms were examined for potentially interfering peaks.
RESULTS
Typical chromatograms are shown in Fig. 1 the assay to work correctly. For the most part, these were discovered by trail and error. These details involve the use of DMSO and SDS in dissolving amphotericin B, the use of SDS to stabilize the drug in solution, the use of guanidine hydrochloride in the extraction procedure, the use of the reversed-phase phenyl extraction columns, the use of EDTA in extraction and analytical buffers, the composition of the mobile phase used in chromatography, and the choice of wavelength for quantitation of the drug. Each of these points will now be discussed in detail.
Use of DMSO and SDS. Amphotericin B is poorly soluble in nearly every solvent except DMSO (1) . Because of its unique solubility in DMSO, amphotericin B powder was dissolved in that solvent as the initial step in the preparation of standard solutions. Although the drug was freely soluble in DMSO, it was not well preserved in this solvent. Consequently, solutions in DMSO were immediately mixed with aqueous SDS, which was found to confer greatly increased stability. The drug powder could not be dissolved directly in SDS or sodium deoxycholate. The stability of amphotericin B in the presence of detergents and its instability in other solutions suggested the use of a standard dissolved in SDS rather than in serum. The amount of SDS (0.25 mg) in 1 ml of working standard solution did not interfere with the extraction, but larger amounts (over 0.5 mg) caused incomplete recovery of the ISTD. As discussed above, the addition of SDS to the sample extract increased its stability. SDS also increased by about 30 s the retention time of amphotericin B on the analytical column and sharpened the peak, both presumably by an ion-pairing mechanism. Use of guanidine. Guanidine hydrochloride was needed to effect complete recovery of both amphotericin B and the ISTD. Urea, another common denaturant, could not be substituted for guanidine. With guanidine present, complete recovery was obtained at pH 5 but not at pH 8.5. The necessity of using a strong protein denaturant such as guanidine in the extraction can be explained by the fact that amphotericin B is strongly bound to serum proteins (2) and must be released before extraction.
The stability of the ISTD in guanidine was good in contrast to that of amphotericin B. The problem this creates can be circumvented by keeping to 5 min or less the time the specimen is exposed to guanidine. If this is done, loss of amphotericin B is less than 4% (based on its half-life of 1.5 h in guanidine).
Choice of extraction column. A phenyl, rather than the more commonly used octadecylsilyl (C18), extraction column was necessary for complete extraction of the drug and the ISTD. Apparently, the aromatic phenyl groups of the phenyl column have higher affinity than the aliphatic octadecyl groups of the octadecylsilyl column for both the conjugated polyene of amphotericin B and the fused aromatic rings of the ISTD.
Importance of EDTA. Amphotericin B could not be released quantitatively from the extraction column by elution with large volumes of methanol, acetonitrile, or even DMSO. A variable, usually large amount of drug could be recovered by elution of the column with a combination of acetonitrile and aqueous EDTA. This finding is consistent with the observation of Nilsson-Ehle et al. (8) that amphotericin B peaks eluting from their C18 column were neither quantitative nor reproducible in the absence of EDTA. EDTA was therefore included in the mobile phase for the analytical column also. The mechanism of the EDTA effect is unknown. Citrate, another metal ion chelator, had no such effect.
Mobile-phase composition. The composition of the mobile phase (acetonitrile-methanol-EDTA) was chosen so that amphotericin B and the ISTD would move away from each other and from various interfering peaks endogenous to serum. The retention time of amphotericin B was greatly influenced by solvent composition. In acetonitrile-EDTA, for example, it eluted well before the ISTD (see Fig. 1 ).
Choice of wavelength. The absorption spectrum of amphotericin B has sharp maxima at 409, 386, 367, and 349 nm in aqueous ethanol (1) . Nilsson-Ehle et al. used the 409-nm peak for detection because it is the most intense of the four and was found to be least subject to interference in hemolyzed specimens (8) . The use of 386 nm in the method described in the present paper was a second choice. The LC-65T Detector-Oven did not have a visible light source, and I I 4 its deuterium (UV) lamp provided insufficient energy at 409 nm. Because the 386-nm peak of amphotericin B is only slightly less intense than the 409-nm peak and because my method included an extractioni step which eliminated interference caused by hemolysis (8) Correlation between the bioassay and the chromatographic assay (Table 1) was poor, as expected. This can be attributed to the imprecision inherent in any tube dilution method. This imprecision was the primary incentive for the development of the chromatographic assay.
It is interesting to consider how the observed chemical behavior of amphotericin B may help to explain its pharmacokinetic behavior. The stability of amphotericin B in the presence of detergents is well documented (1, 10) . The protective effect of SDS was striking in view of the instability of the drug in DMSO, aqueous acetonitrile, and serum. Apparently, either the drug bound in detergent micelles is inaccessible to more polar molecules which can react with it or the drug is "frozen" into a sterically nonreactive configuration (11) . This may explain why the drug was found to be much less stable in serum mixed with guanidine than in serum alone. Guanidine presumably released it from serum protein to which it was bound and rendered it more vulnerable to chemical attack. It is not likely that guanidine itself reacted with the drug. This behavior also suggests an explanation for some of the reported peculiar pharmocokinetics of amphotericin B (2, 4, 9) . After a course of therapy with amphotericin B, the level of the drug in plasma decreases very slowly, with a half-life of about 2 weeks. Most of the drug is neither excreted in the urine or feces nor metabolized enzymatically by the liver but simply "disappears." Atkinson and Bennett (2) speculate that the drug is stored in the plasma membranes of muscle and skin cells and is slowly released into the circulation. Because it is stabilized in detergent micells and phospholipid vesicles (11) , it may similarly be stabilized in lipid bilayers. Also, because it is destroyed nonenzymatically in aqueous solutions, it may similarly be destroyed in the bloodstream.
